OpenURL Connection Search

Select item for more details and to access through your institution.

ABSTRACTS.
Published in:
2002
By:
- Bradley, E.H.;
- Hallemeier, A.G.;
- Fried, T.R.;
- Johnson-Hurzeler, R.;
- Cherlin, E.J.;
- Kasl, S.V.;
- Horwitz, S.M.;
- Cha, K.Y.;
- Wirth, D.P.;
- Lobo, R.A.;
- Eisenberg, D.M.;
- Kessler, R.C.;
- Van Rompay, M.I.;
- Kaptchuck, T.J.;
- Wilkey, S.A.;
- Appel, S.;
- Davis, R.B.;
- Keller, K.
Publication type:
Abstract
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
By:
- Horwitz, S.M.;
- Scarisbrick, J.;
- Prince, H.M.;
- Whittaker, S.;
- Duvic, M.;
- Kim, Y.H.;
- Quaglino, P.;
- Zinzani, P.L.;
- Bechter, O.;
- Eradat, H.;
- Pinter‐Brown, L.;
- Akilov, O.;
- Geskin, L.;
- Sanches, J.;
- Ortiz‐Romero, P.;
- Lisano, J.;
- Brown, L.;
- Palanca‐Wessels, M.C.;
- Gautam, A.;
- Bunn, V.
Publication type:
Article
ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT.
Published in:
Hematological Oncology, 2019, v. 37, p. 283, doi. 10.1002/hon.93_2630
By:
- Shustov, A.;
- Cabrera, M.;
- Bellei, M.;
- Civallero, M.;
- Ko, Y.H.;
- Manni, M.;
- Horwitz, S.M.;
- Antonio De Souza, C.;
- Radford, J.;
- Varela, S.B.;
- Prates, M.V.;
- Ferreri, A.;
- Chiattone, C.;
- Spina, M.;
- Vose, J.M.;
- Chiappella, A.;
- Laszlo, D.;
- Marino, D.;
- Stelitano, C.;
- Skrypets, T.
Publication type:
Article
INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS.
Published in:
Hematological Oncology, 2019, v. 37, p. 264, doi. 10.1002/hon.74_2630
By:
- Rajeeve, S.;
- Bobillo, S.V.;
- Zelenetz, A.D.;
- Straus, D.J.;
- Palomba, M.L.;
- Noy, A.;
- Horwitz, S.M.;
- Moskowitz, A.J.;
- Hamlin, P.A.;
- Matasar, M.J.;
- Kumar, A.;
- Batlevi, C.L.;
- Keudell, G.;
- Yahalom, J.;
- Dogan, A.;
- Drill, E.;
- Younes, A.;
- Joffe, E.
Publication type:
Article
RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA‐ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 97, doi. 10.1002/hon.62_2629
By:
- Ghione, P.;
- Cordeiro, P.G.;
- Ni, A.;
- Hu, Q.;
- Ganesan, N.;
- Galasso, N.;
- Dogan, A.;
- Horwitz, S.M.
Publication type:
Article
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial.
Published in:
Hematological Oncology, 2019, v. 37, p. 65, doi. 10.1002/hon.33_2629
By:
- Horwitz, S.M.;
- Foss, F.M.;
- Porcu, P.;
- Moskowitz, A.;
- Mehta‐Shah, N.;
- Jacobsen, E.;
- Khodadoust, M.S.;
- Kim, Y.H.;
- Weinstock, D.;
- Lustgarten, S.;
- Baglio, M.;
- Youssoufian, H.;
- Brammer, J.
Publication type:
Article
TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA TREATED WITH MODIFIED (m)SMILE AND INTENSITY‐MODULATED RADIOTHERAPY (IMRT), A SINGLE CENTER EXPERIENCE.
Published in:
Hematological Oncology, 2019, v. 37, p. 477, doi. 10.1002/hon.156_2631
By:
- Ghione, P.;
- Qi, S.;
- Imber, B.S.;
- Venkatraman, S.;
- Moskowitz, A.;
- Galasso, N.;
- Lunning, M.;
- Straus, D.;
- Sauter, C.;
- Dahi, P.;
- Dogan, A.;
- Yahalom, J.;
- Horwitz, S.M.
Publication type:
Article
IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 152, doi. 10.1002/hon.109_2629
By:
- Batlevi, C.L.;
- Sha, F.;
- Alperovich, A.;
- Ni, A.;
- Smith, K.;
- Ying, Z.;
- Hamlin, P.;
- Horwitz, S.M.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.J.;
- Moskowitz, C.H.;
- Noy, A.;
- Palomba, M.L.;
- Portlock, C.;
- Straus, D.;
- Boccomini, C.;
- Tucci, A.;
- Zelenetz, A.D.;
- Seshan, V.E.
Publication type:
Article
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 286, doi. 10.1002/hon.96_2630
By:
- Horwitz, S.M.;
- Scarisbrick, J.;
- Prince, H.M.;
- Whittaker, S.;
- Duvic, M.;
- Kim, Y.H.;
- Quaglino, P.;
- Zinzani, P.L.;
- Bechter, O.;
- Eradat, H.;
- Pinter‐Brown, L.;
- Akilov, O.;
- Geskin, L.;
- Sanches, J.;
- Ortiz‐Romero, P.;
- Lisano, J.;
- Brown, L.;
- Palanca‐Wessels, M.C.;
- Gautam, A.;
- Bunn, V.
Publication type:
Article
ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT.
Published in:
Hematological Oncology, 2019, v. 37, p. 283, doi. 10.1002/hon.93_2630
By:
- Shustov, A.;
- Cabrera, M.;
- Bellei, M.;
- Civallero, M.;
- Ko, Y.H.;
- Manni, M.;
- Horwitz, S.M.;
- Antonio De Souza, C.;
- Radford, J.;
- Varela, S.B.;
- Prates, M.V.;
- Ferreri, A.;
- Chiattone, C.;
- Spina, M.;
- Vose, J.M.;
- Chiappella, A.;
- Laszlo, D.;
- Marino, D.;
- Stelitano, C.;
- Skrypets, T.
Publication type:
Article
INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS.
Published in:
Hematological Oncology, 2019, v. 37, p. 264, doi. 10.1002/hon.74_2630
By:
- Rajeeve, S.;
- Bobillo, S.V.;
- Zelenetz, A.D.;
- Straus, D.J.;
- Palomba, M.L.;
- Noy, A.;
- Horwitz, S.M.;
- Moskowitz, A.J.;
- Hamlin, P.A.;
- Matasar, M.J.;
- Kumar, A.;
- Batlevi, C.L.;
- Keudell, G.;
- Yahalom, J.;
- Dogan, A.;
- Drill, E.;
- Younes, A.;
- Joffe, E.
Publication type:
Article
RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA‐ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 97, doi. 10.1002/hon.62_2629
By:
- Ghione, P.;
- Cordeiro, P.G.;
- Ni, A.;
- Hu, Q.;
- Ganesan, N.;
- Galasso, N.;
- Dogan, A.;
- Horwitz, S.M.
Publication type:
Article
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial.
Published in:
Hematological Oncology, 2019, v. 37, p. 65, doi. 10.1002/hon.33_2629
By:
- Horwitz, S.M.;
- Foss, F.M.;
- Porcu, P.;
- Moskowitz, A.;
- Mehta‐Shah, N.;
- Jacobsen, E.;
- Khodadoust, M.S.;
- Kim, Y.H.;
- Weinstock, D.;
- Lustgarten, S.;
- Baglio, M.;
- Youssoufian, H.;
- Brammer, J.
Publication type:
Article
TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA TREATED WITH MODIFIED (m)SMILE AND INTENSITY‐MODULATED RADIOTHERAPY (IMRT), A SINGLE CENTER EXPERIENCE.
Published in:
Hematological Oncology, 2019, v. 37, p. 477, doi. 10.1002/hon.156_2631
By:
- Ghione, P.;
- Qi, S.;
- Imber, B.S.;
- Venkatraman, S.;
- Moskowitz, A.;
- Galasso, N.;
- Lunning, M.;
- Straus, D.;
- Sauter, C.;
- Dahi, P.;
- Dogan, A.;
- Yahalom, J.;
- Horwitz, S.M.
Publication type:
Article
IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 152, doi. 10.1002/hon.109_2629
By:
- Batlevi, C.L.;
- Sha, F.;
- Alperovich, A.;
- Ni, A.;
- Smith, K.;
- Ying, Z.;
- Hamlin, P.;
- Horwitz, S.M.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.J.;
- Moskowitz, C.H.;
- Noy, A.;
- Palomba, M.L.;
- Portlock, C.;
- Straus, D.;
- Boccomini, C.;
- Tucci, A.;
- Zelenetz, A.D.;
- Seshan, V.E.
Publication type:
Article
BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION.
Published in:
Hematological Oncology, 2017, v. 35, p. 77, doi. 10.1002/hon.2437_65
By:
- Kim, Y.H.;
- Prince, H.M.;
- Whittaker, S.;
- Horwitz, S.M.;
- Duvic, M.;
- Scarisbrick, J.;
- Quaglino, P.;
- Zinzani, P.L.;
- Wolter, P.;
- Bechter, O.;
- Wang, Y.;
- Palanca ‐ Wessels, M.C.;
- Wood, K.W.;
- Li, M.;
- Liu, Y.;
- Lin, H.;
- Little, M.;
- Danaee, H.;
- Trepicchio, W.;
- Dummer, R.
Publication type:
Article
IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT.
Published in:
Hematological Oncology, 2017, v. 35, p. 78, doi. 10.1002/hon.2437_66
By:
- Fox, C.P.;
- Bellei, M.;
- Manni, M.;
- Kim, S.J.;
- Ko, Y.H.;
- Shustov, A.R.;
- Cabrera, M.E.;
- Chiattone, C.S.;
- Horwitz, S.M.;
- Spina, M.;
- Advani, R.H.;
- Angrilli, F.;
- De Souza, C.A.;
- Dlouhy, I.;
- Fernandez ‐ Alvarez, R.;
- Gabús, R.;
- Hitz, F.;
- Laszlo, D.;
- Montoto, S.;
- Nagler, A.
Publication type:
Article
INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT-301, A NOVEL PYRROLOBENZODIAZAPINE-BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON-HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 270, doi. 10.1002/hon.2438_143
By:
- Horwitz, S.M.;
- Fanale, M.A.;
- Spira, A.I.;
- Havenith, K.;
- He, S.;
- Feingold, J.M.;
- Hamadani, M.
Publication type:
Article
TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 230, doi. 10.1002/hon.2438_93
By:
- Soumerai, J.D.;
- Ni, A.;
- Batlevi, C.;
- Alperovich, A.;
- Bantilan, K.S.;
- Palomba, M.;
- Gerecitano, J.F.;
- Noy, A.;
- Hamlin, P.;
- Moskowitz, C.H.;
- Copeland, A.R.;
- Matasar, M.J.;
- Drullinsky, P.R.;
- Hamilton, A.;
- Horwitz, S.M.;
- Intlekofer, A.M.;
- Kumar, A.;
- Moskowitz, A.;
- Portlock, C.;
- Sauter, C.
Publication type:
Article

Found: 19